National Pension Service raised its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 4.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 72,009 shares of the biopharmaceutical company’s stock after purchasing an additional 2,763 shares during the period. National Pension Service’s holdings in Regeneron Pharmaceuticals were worth $27,073,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Shell Asset Management Co. boosted its holdings in Regeneron Pharmaceuticals by 24.1% in the 3rd quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock valued at $5,565,000 after purchasing an additional 2,999 shares during the period. Northpointe Capital LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $2,089,000. Cubist Systematic Strategies LLC boosted its holdings in Regeneron Pharmaceuticals by 176.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 428 shares during the period. Griffin Asset Management Inc. bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $1,579,000. Finally, Prentiss Smith & Co. Inc. bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $416,000. 66.63% of the stock is owned by hedge funds and other institutional investors.

Shares of Regeneron Pharmaceuticals Inc (REGN) opened at $371.53 on Friday. Regeneron Pharmaceuticals Inc has a fifty-two week low of $340.09 and a fifty-two week high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The company has a market cap of $39,889.95, a PE ratio of 33.74, a price-to-earnings-growth ratio of 1.43 and a beta of 1.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same quarter in the prior year, the firm earned $3.13 EPS. The company’s revenue was up 23.0% on a year-over-year basis. equities analysts forecast that Regeneron Pharmaceuticals Inc will post 13.55 earnings per share for the current year.

A number of analysts have weighed in on REGN shares. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th. Barclays downgraded shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their price target for the company from $450.00 to $395.00 in a report on Friday, October 20th. Guggenheim reissued a “buy” rating and issued a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $490.00 price target (up from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $471.11.

ILLEGAL ACTIVITY WARNING: “National Pension Service Raises Holdings in Regeneron Pharmaceuticals Inc (REGN)” was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/01/20/national-pension-service-raises-holdings-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.